Investor search results
712 investors found
🌍 United States📊 early stage🏷 Therapeutics
Popular searches

Caroline Farah Lembck, MBA, PhD (abd)
American Businesswoman, Investor & Entrepreneur Founder of LemVega Capital®, Puerto Rico’s leading investment firm going global | Featured NasDaq, Forbes | BA at 19 years old | MBA at 20 | PhD started at 20 | CEO at 21
11
in Therapeutics

Tim Walbert
Managing Partner, HRZN Partners LLC; Sr. Advisor, Amgen; Sr. Advisor, Patient Square Capital
9
in Therapeutics
Frequently asked questions about Therapeutics investors in United States
How many Therapeutics early-stage investors are there in United States?
Gritt tracks 710 Therapeutics early-stage investors in United States, of which 557 (78%) have a direct email address available.
How can I contact Therapeutics investors in United States?
Gritt provides direct email addresses for 78% of investors in this list. On a paid plan you can unlock them and export the list, or use Gritt AI outreach to draft personalised emails that you approve, or let Gritt approve, and send from your Gmail.
Are these investors actively investing in United States startups?
Gritt lists them most active first, by the number of deals they have made in Therapeutics, and each profile shows those deals and their dates. To see only investors who have invested recently, use the Last active filter.
Can I filter by investment stage or industry?
Yes — use the filters on the left to narrow by investment stage (early, mid, late) or industry. You can also filter by last active date to focus on investors who have made deals recently.
Can I export this list of Therapeutics investors in United States?
Yes — paid Gritt accounts can export any filtered investor list as a CSV, including names, email addresses, LinkedIn profiles and investment counts.
Contact all 710 Therapeutics early-stage investors
Gritt drafts a personalised AI email for each — written from your pitch; you approve each one, or let Gritt approve them for you, and it sends from your Gmail.
Start free — contact these investors





